Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1

Conditions

Multiple Myeloma 155Lymphoma 20Recurrence 17Neoplasms 12Hematologic Neoplasms 11Neoplasms, Plasma Cell 9Lymphoma, Non-Hodgkin 9Immunoglobulin Light-chain Amyloidosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Smoldering Multiple Myeloma 4Prostatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Plasma Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Breast Neoplasms 4Ovarian Neoplasms 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Cytokine Release Syndrome 3Waldenstrom Macroglobulinemia 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

selinexor 1pazopanib 1Proton Therapy 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vascular Neoplasms × Plasma cell × 30 days × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡